

Special Issue

Cancer Immunotherapy and Immune-Related Adverse Events

Message from the Guest Editor

Cancer immunotherapy has shown remarkable success in the treatment of diverse cancer types. It utilizes the power of the immune system to recognize and attack cancer cells. The main types of cancer immunotherapies include immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cytokines, immunomodulators, cancer vaccines, monoclonal antibodies, and oncolytic viruses. Although immunotherapy has emerged as a highly promising treatment option, a significant number of patients develop unpredictable and potentially severe immune-related adverse events (irAEs). For the optimal treatment and management of patients, it is critical to resolve the issues caused by immunotherapies, understand the mechanisms underlying irAEs, and identify biomarkers predictive of irAEs. Thus, the aim of this Special Issue is to highlight recent studies on immune-related adverse events associated with cancer immunotherapy. We will present original research and review articles addressing our current understanding of, novel studies on, and advancements pertaining to irAEs associated with cancer immunotherapies.

Guest Editor

Dr. Shaheen Khan

Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9093, USA

Deadline for manuscript submissions

closed (15 July 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/68591

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)